Skip Navigation


European Heart Journal Advance Access originally published online on May 12, 2006
European Heart Journal 2006 27(12):1505-1506; doi:10.1093/eurheartj/ehi888
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/12/1505-a    most recent
ehi888v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Husted, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Husted, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Dyspnoea after AZD6140: safety first?: reply

Steen Husted

Department of Cardiology
Aarhus Sygehus
Tage Hansens Gade 2
Arhus C 8000
Denmark
Tel: +45 89 497613
Fax: +45 89 497619
E-mail address: steen.husted@as.aaa.dk

The first 10% of the full text of this article appears below.

I would like to thank Dr Serebruany for his interest in our manuscript. In his letter, he expressed concern about the adverse event of dyspnoea reported in the Phase 2a study of the reversible, oral P2Y12 antagonist, AZD6140.1 Results describes the 23 patients with reported dyspnoea, none of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?